Journal
JOURNAL OF CLINICAL AND TRANSLATIONAL SCIENCE
Volume 5, Issue 1, Pages -Publisher
CAMBRIDGE UNIV PRESS
DOI: 10.1017/cts.2020.39
Keywords
COVID-19; SARS-CoV-2; coronavirus; antibody-dependent enhancement; Fc receptor; vaccine; antibody
Categories
Funding
- National Institutes of Health Institute of Allergy, Immunology and Infectious Diseases [R21 AI138500]
- University of Rochester Clinical and Translational Science from the National Center for Advancing Translational Sciences [UL1 TR002001]
Ask authors/readers for more resources
The article discusses the evidence of ADE in SARS-CoV-2 infection and how to address this potential translational barrier to vaccine development.
There is an urgent need for vaccines to the 2019 coronavirus (COVID19; SARS-CoV-2). Vaccine development may not be straightforward, due to antibody-dependent enhancement (ADE). Antibodies against viral surface proteins can, in some cases, increase infection severity by ADE. This phenomenon occurs in SARS-CoV-1, MERS, HIV, Zika, and dengue virus infection and vaccination. Lack of high-affinity anti-SARS-CoV-2 IgG in children may explain the decreased severity of infection in these groups. Here, we discuss the evidence for ADE in the context of SARS-CoV-2 infection and how to address this potential translational barrier to vaccine development, convalescent plasma, and targeted monoclonal antibody therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
